446 related articles for article (PubMed ID: 23867133)
1. The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer's disease-related molecules induced by herpes simplex virus type 1.
Wozniak MA; Frost AL; Itzhaki RF
Antiviral Res; 2013 Sep; 99(3):401-4. PubMed ID: 23867133
[TBL] [Abstract][Full Text] [Related]
2. Antivirals reduce the formation of key Alzheimer's disease molecules in cell cultures acutely infected with herpes simplex virus type 1.
Wozniak MA; Frost AL; Preston CM; Itzhaki RF
PLoS One; 2011; 6(10):e25152. PubMed ID: 22003387
[TBL] [Abstract][Full Text] [Related]
3. Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor.
Yajima M; Yamada H; Takemoto M; Daikoku T; Yoshida Y; Long T; Okuda T; Shiraki K
Antiviral Res; 2017 Mar; 139():95-101. PubMed ID: 28027917
[TBL] [Abstract][Full Text] [Related]
4. Amyloid-β and p-Tau Anti-Threat Response to Herpes Simplex Virus 1 Infection in Primary Adult Murine Hippocampal Neurons.
Powell-Doherty RD; Abbott ARN; Nelson LA; Bertke AS
J Virol; 2020 Apr; 94(9):. PubMed ID: 32075924
[TBL] [Abstract][Full Text] [Related]
5. A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target.
Biswas S; Kleymann G; Swift M; Tiley LS; Lyall J; Aguirre-Hernández J; Field HJ
J Antimicrob Chemother; 2008 May; 61(5):1044-7. PubMed ID: 18299638
[TBL] [Abstract][Full Text] [Related]
6. Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture.
Biswas S; Jennens L; Field HJ
Arch Virol; 2007; 152(8):1489-500. PubMed ID: 17404685
[TBL] [Abstract][Full Text] [Related]
7. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.
Crute JJ; Grygon CA; Hargrave KD; Simoneau B; Faucher AM; Bolger G; Kibler P; Liuzzi M; Cordingley MG
Nat Med; 2002 Apr; 8(4):386-91. PubMed ID: 11927945
[TBL] [Abstract][Full Text] [Related]
8. Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus.
Field HJ; Biswas S
Drug Resist Updat; 2011 Feb; 14(1):45-51. PubMed ID: 21183396
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin reduces β amyloid and abnormal tau formation caused by herpes simplex virus type 1.
Wozniak MA; Itzhaki RF
J Neuroimmunol; 2013 Apr; 257(1-2):7-12. PubMed ID: 23385080
[TBL] [Abstract][Full Text] [Related]
10. Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1.
Duan J; Liuzzi M; Paris W; Liard F; Browne A; Dansereau N; Simoneau B; Faucher AM; Cordingley MG
Antimicrob Agents Chemother; 2003 Jun; 47(6):1798-804. PubMed ID: 12760851
[TBL] [Abstract][Full Text] [Related]
11. Helicase-primase inhibitors for herpes simplex virus: looking to the future of non-nucleoside inhibitors for treating herpes virus infections.
Biswas S; Sukla S; Field HJ
Future Med Chem; 2014 Jan; 6(1):45-55. PubMed ID: 24358947
[TBL] [Abstract][Full Text] [Related]
12. Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity.
Biswas S; Tiley LS; Zimmermann H; Birkmann A; Field HJ
Antiviral Res; 2008 Oct; 80(1):81-5. PubMed ID: 18539344
[TBL] [Abstract][Full Text] [Related]
13. High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1.
Biswas S; Swift M; Field HJ
Antivir Chem Chemother; 2007; 18(1):13-23. PubMed ID: 17354648
[TBL] [Abstract][Full Text] [Related]
14. Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques.
Wozniak MA; Mee AP; Itzhaki RF
J Pathol; 2009 Jan; 217(1):131-8. PubMed ID: 18973185
[TBL] [Abstract][Full Text] [Related]
15. Helicase-primase as a target of new therapies for herpes simplex virus infections.
James SH; Larson KB; Acosta EP; Prichard MN
Clin Pharmacol Ther; 2015 Jan; 97(1):66-78. PubMed ID: 25670384
[TBL] [Abstract][Full Text] [Related]
16. Antiviral therapy: Valacyclovir Treatment of Alzheimer's Disease (VALAD) Trial: protocol for a randomised, double-blind,placebo-controlled, treatment trial.
Devanand DP; Andrews H; Kreisl WC; Razlighi Q; Gershon A; Stern Y; Mintz A; Wisniewski T; Acosta E; Pollina J; Katsikoumbas M; Bell KL; Pelton GH; Deliyannides D; Prasad KM; Huey ED
BMJ Open; 2020 Feb; 10(2):e032112. PubMed ID: 32034019
[TBL] [Abstract][Full Text] [Related]
17. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
[TBL] [Abstract][Full Text] [Related]
18. Helicase primase: targeting the Achilles heel of herpes simplex viruses.
Kleymann G
Antivir Chem Chemother; 2004 May; 15(3):135-40. PubMed ID: 15266895
[TBL] [Abstract][Full Text] [Related]
19. Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir).
Chono K; Katsumata K; Kontani T; Shiraki K; Suzuki H
Biochem Pharmacol; 2012 Aug; 84(4):459-67. PubMed ID: 22687623
[TBL] [Abstract][Full Text] [Related]
20. Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase.
Liuzzi M; Kibler P; Bousquet C; Harji F; Bolger G; Garneau M; Lapeyre N; McCollum RS; Faucher AM; Simoneau B; Cordingley MG
Antiviral Res; 2004 Dec; 64(3):161-70. PubMed ID: 15550269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]